Company Overview

Dysregulated lncRNAs recruit RNA-binding proteins (RBPs) to drive pathological processes across disease areas.

NextRNA's therapeutic approach centers on inhibiting the function of lncRNAs by disrupting the interaction between lncRNAs and RBPs with small molecules. NextRNA’s strategy is  differentiated in that it offers optionality to target the lncRNA or the RBP side of the interaction.